Showing results (51-60 of 69) with videos related to
Sort By:
Pageof 7
Gut|October 23, 2013
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementationAd A van Bodegraven, Nathalie Bravenboer, Birgit I Witte, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2018
High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel DiseaseShailja C Shah, Joren R Ten Hove, Daniel Castaneda, et al.Lancet (London, England)|July 19, 2017
Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trialMarin J de Jong, Andrea E van der Meulen-de Jong, Mariëlle J Romberg-Camps, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 20, 2019
Risk of impaired nutritional status and flare occurrence in IBD outpatientsCorinne E G M Spooren, Dion S J Wintjens, Marin J de Jong, et al.Journal of Crohn'S & Colitis|July 19, 2015
Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-Based IBDSL CohortSteven F G Jeuring, Paul H A Bours, Maurice P Zeegers, et al.Inflammatory Bowel Diseases|January 24, 2013
Adenomas in patients with inflammatory bowel disease are associated with an increased risk of advanced neoplasiaFiona D M van Schaik, Erik Mooiweer, Mike van der Have, et al.Plos One|August 29, 2025
Lifestyle and psychosocial factors in inflammatory bowel disease: Prevalence, impact, motivation, and support needsKarlijn Demers, Evelien M B Hendrix, Ashkan Rezazadeh Ardabili, et al.Lancet (London, England)|February 26, 2008
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialGeert D'Haens, Filip Baert, Gert van Assche, et al.Alimentary Pharmacology & Therapeutics|October 25, 2022
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC RegistryTessa Straatmijer, Fiona D M van Schaik, Alexander G L Bodelier, et al.Plos One|April 22, 2016
Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-UpMirthe E van der Valk, Marie-Josée J Mangen, Mirjam Severs, et al.Pageof 7